News | Contrast Media | April 13, 2016

Global Contrast Media Market to Surpass $6 Billion by 2022

GlobalData report cites increasing burden for diagnostic scans, lack of outside competition

April 13, 2016 — The global market for contrast media is set to rise from just over $4.3 billion in 2015 to over $6 billion by 2022, according to research and consulting firm GlobalData. This represents a compound annual growth rate of 4.9 percent.

The company’s latest report states that this growth — which will occur across the 10 major markets (10MM) of the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, Brazil, China and India — will be driven by a number of factors. These include increases in the number of annual computed tomography (CT), magnetic resonance imaging (MRI) and echocardiogram procedures as well as an increasing disease burden across the 10MM.

Amendeep Sanghera, GlobalData’s analyst covering medical devices, explained, “The contrast media market is old and well-established, with products being used in a wide array of indications. As populations rise across the global, disease rates inevitably grow, along with the need for diagnostic investigations and therefore contrast media.

“Better healthcare systems and education across numerous regions are also driving the contrast media market. For example, there is a particular focus in developed countries to screen patients for certain diseases such as breast and colorectal cancer in order to catch disease early and increase the likelihood of a patient’s survival, and this practice is now spreading to developing countries.”

GlobalData’s report also states that the market has no real competition besides the players already in it, as no other non-invasive imaging modality is able to provide comparative results as quickly, safely and easily to patients. However, generic contrast media manufacturers may acquire market share if they are able develop a reputable brand provided at a lower cost than the four leading market players: GE Healthcare, Bayer, Bracco and Guerbet.

Sanghera added, “Due to excellent safety profiles, image enhancement and wide indication coverage, contrast media have become a mainstay of modern medicine. Nuclear medicine could be a competitor in the future, but for now the contrast media market is in a stable position.”

For more information: www.globaldata.com

Related Content

VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
Overlay Init